A Study on the Efficacy of Proton Pump Inhibitors in *Helicobacter pylori*-Negative Primary Care Patients with Dyspepsia in Japan

Tomoari Kamada*, Yoshinori Fujimura†, Kensuke Gotoh‡, Hiroshi Imamura§, Noriaki Manabe†, Hiroaki Kusunoki§, Kazuhiko Inoue¶, Akiko Shiotani*, Jiro Hata†, and Ken Haruma*

*Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical School, Kurashiki, †Division of Endoscopy and Ultrasound, Department of Clinical Pathology and Laboratory Medicine, and ‡Department of General Medicine, Kawasaki Medical School, Kurashiki, Japan

**Background/Aims:** There have been few studies on the efficacy of proton pump inhibitors and the doses required to treat dyspeptic symptoms observed in clinical practice. The aim of this study was to compare the efficacy of different doses of omeprazole and different administration methods in *Helicobacter pylori*-negative, dyspeptic patients. **Methods:** Patients with chronic upper abdominal symptoms within the previous 3 months were randomly divided into three groups: a daily, omeprazole 20 mg treatment group (OPZ20, n=61); a daily, omeprazole 10 mg treatment group (OPZ10, n=72); and an on-demand omeprazole 20 mg treatment group (on-demand, n=62). After 4 weeks of administration of the drug, symptom improvement rates were evaluated based on the Overall Global Severity score. **Results:** The rates of symptom improvement after 4 weeks of treatment were 65.6% (40/61) in the OPZ20 group, 47.2% (34/72) in the OPZ10 group, and 50.0% (31/62) in the on-demand group. The OPZ20 group exhibited a significantly higher improvement rate (p=0.034) than the OPZ10 group. The OPZ20 group had significant improvements in regurgitation, postprandial fullness, vomiting, and bloating compared with the OPZ10 group. **Conclusions:** Daily treatment with 20 mg of omeprazole was efficient in treating upper abdominal symptoms. Trial registration: ClinicalTrials.gov, number UMIN000002621. (Gut Liver 2013;7:16-22)

**Key Words:** Dyspepsia; Proton pump inhibitors; Omeprazole; Primary health care

**INTRODUCTION**

Functional dyspepsia (FD) is a symptomatically defined clinical disorder, of which the diagnosis is based on chronic or recurrent symptoms thought to originate from the upper gastrointestinal (GI) tract, with the absence of organic diseases likely to explain the symptoms. In addition, according to the Rome III criteria, there is a new classification including two distinct diagnostic categories, i.e., postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS), which indicate meal-related and unrelated symptoms, respectively. The primary symptom of FD is epigastric pain or discomfort and other symptoms include excessive burping/belching, upper abdominal bloating, nausea, and a feeling of abnormal or slow indigestion or early satiety.

Dyspepsia is a relatively common health problem in the world. The reported prevalence of this condition in Japan is 13% and a rate of 28% has been shown in an international surveillance study. In addition, it is estimated that 20% to 25% of the population in Western countries is affected by dyspepsia at any time. Although mortality related to dyspepsia is rare, the burden on health-care systems is substantial due to the chronic and recurrent nature of this disorder. FD, which is a common condition found in primary care patients, decreases a person’s quality of life and results in huge economic loss because of direct expenses from medical care and indirect costs from sick leaves and sickness pensions.

Gastroesophageal reflux disease (GERD), peptic ulcer diseases, and FD are very prevalent in outpatient settings. These acid-related and/or functional disorders of the upper GI tract are currently treated with antisecretory compounds, including histamine-$H_{2}$-receptor antagonists (H$_{2}$RA) and proton pump inhibitor (PPI). The efficacy of PPI in FD is well-known. There are many
well designed studies, including meta-analysis.\textsuperscript{3-12} PPIs are more potent in reducing gastric acid than H,RAs; therefore, they are the most important drugs in practical medicine. In FD patients, among various medications examined in clinical trials, both PPIs and prokinetic therapies have demonstrated to be superior to placebo.\textsuperscript{13-16} However, a standard management modality for FD has not yet been established. A recent study\textsuperscript{17} showed that treatment with omeprazole provides superior symptom relief compared to ranitidine, cisapride, and placebo treatment in \textit{Helicobacter pylori}-negative dyspeptic patients receiving primary care in Canada. However, the management of \textit{H. pylori}-negative primary care patients with uninvestigated dyspepsia has not been studied in Japan.

The objective of our study was to compare the efficacy of different doses of omeprazole and different administration methods in \textit{H. pylori}-negative dyspeptic patients at 4 weeks of treatment.

\textbf{MATERIALS AND METHODS}

\textbf{1. Study design}

This was a multicenter, single-blind (only patients were blinded) designed study. Allocation to treatment was assigned in equal numbers (1:1:1) using a centrally generated randomization list stratified for each center in blocks of 3. All patients remained blinded to treatment allocation for the duration of the study. Patients were enrolled at three centers (two hospitals and one primary clinic) from April 2009 until September 2009. The study protocol was approved by the local ethics committees, and written informed consent was obtained from each patient.

\textbf{2. Selection of patients}

The age range of the patients was from 20 to 65 years old, and patients had uninvestigated chronic or recurrent upper GI symptoms of stomach pain, heartburn, acid regurgitation, post-prandial fullness, vomiting, belching, early satiety, or bloating within the past 3 months. The Global Overall Symptom (GOS) score\textsuperscript{18} was recorded at baseline. Moderate to severe symptoms were defined as GOS score of 4 and above in patient-reported symptom questionnaires using a 7-point Likert scale. Patients with “alarm” symptoms (such as vomiting, evidence of bleeding, and inadvertent weight loss) warranting an endoscopy were excluded. Patients were also excluded if they had undergone investigations by upper endoscopy and/or GI barium studies within 3 months prior to randomization. They were also excluded if they had taken any GI drugs, antidepressants, steroids, non-steroidal anti-inflammatory drugs, aspirin, or bisphosphonates. However, patients could be enrolled if the drugs were washed out for 1 week before entry and discontinued during the study period. The \textit{H. pylori} infection status was evaluated by employing a 20-minute immunochromatography method for the presence of anti-\textit{H. pylori} immunoglobulin G in urine (RAPIRUN\textsuperscript{19} \textit{H. pylori} Antibody; Otsuka Pharmaceutical Co., Tokyo, Japan).

\textbf{3. Study protocol}

After we obtained informed consent from the patients, baseline severity of symptoms was recorded over a 2-week observation period. Then, we performed the \textit{H. pylori} diagnostic test. If the result was positive for \textit{H. pylori}, the patient was excluded from the study. Eligible patients were randomized to a 4-week treatment course with 20 mg omeprazole (OPZ20, as one tablet), 10 mg omeprazole (OPZ10, as one tablet), or on-demand 20 mg omeprazole (on-demand, as one tablet). We defined the method of on-demand therapy in FD according to the method of GERD,\textsuperscript{20} as follows; the method of on-demand use was explained to the patients in the following way: the patient takes one tablet when the patient complained of troublesome symptoms; however, the dose did not exceed one tablet per day. If moderate or severe symptoms persisted for 3 consecutive days during the maintenance phase of the study, patients were classified as having symptomatic relapse and were requested to attend the hospital for an extra study visit. Other therapies included no rescue medication. Patient compliance was assessed using pill count of returned medication. Patients were considered to have complied with the treatment if they had taken at least 75\% of the dispensed tablets.

We evaluated the symptoms of the patients when they visited the clinic or hospital again after 4 weeks. If medications other than the study drugs were prescribed for dyspepsia, the study drugs were discontinued and the patient was classified as treatment failure. These patients remained in the study and information regarding concomitant medications, tests performed, referrals to specialists, and adverse events was recorded.

\textbf{4. Outcome measures}

The primary outcome measure of the study was the GOS score.\textsuperscript{18} This method measured dyspepsia symptoms over the preceding 4 weeks using a 7-point Likert scale. Severity ranged from 1) no problems, 2) minimal problems—can be easily ignored without effort, 3) mild problems—can be ignored with effort, 4) moderate problems—cannot be ignored but do not influence daily activities, 5) moderately severe problems—cannot be ignored and occasionally limit daily activities, 6) severe problems—cannot be ignored and often limit concentration on daily activities to, and 7) very severe problems—cannot be ignored and markedly limit daily activities and often require rest.

We measured the outcome before the study and after 4 weeks of treatment using this score. For the primary outcome measure, sufficient symptom relief was defined as a score of either 1 (none) or 2 (minimal) on the GOS score after 4 weeks of treatment. The proportion of patients becoming completely asymptomatic (GOS=1) was determined as a secondary outcome. In addition, for the secondary outcome measure, symptom aggravation was defined as an increase in the GOS score by 2 and more after.
21 Patients were excluded

\[ H. pylori\] positive: 15 cases
GOS score, \leq 3: 5 cases
Insufficient report of symptoms: 1 case

217 Enrolled

196 Assessed for eligibility

196 Randomized

62 OPZ20
72 OPZ10
62 On-demand

61 Completed
72 Completed
62 Completed

1 Lost to follow-up

Fig. 1. Flow diagram of study patients.
GOS, Global Overall Symptom; OPZ, omeprazole.

Table 1. Demographic Characteristics of Each Treatment Group

| Characteristic         | OPZ20  | OPZ10  | On-demand |
|------------------------|--------|--------|-----------|
| Gender                 |        |        |           |
| Male                   | 24 (33.8) | 30 (42.3) | 18 (23.9) |
| Female                 | 37 (30.1) | 42 (34.1) | 44 (35.8) |
| Age                    |        |        |           |
| <39 yr                 | 32 (33.3) | 35 (36.5) | 29 (30.2) |
| 40-50 yr               | 16 (32.0) | 17 (34.0) | 17 (34.0) |
| >60 yr                 | 13 (27.1) | 20 (41.7) | 16 (31.2) |
| Mean±SD                | 42.1±17.9 | 46.1±17.7 | 43.9±15.7 |
| BMI                    |        |        |           |
| BMI <20                | 36 (41.4) | 25 (28.7) | 26 (29.9) |
| 20\leq BMI<25          | 19 (20.7) | 39 (44.8) | 31 (34.5) |
| BMI \geq 25            | 6 (31.6)  | 8 (42.1)  | 5 (26.3)  |
| Mean±SD                | 20.3±3.5  | 21.5±2.9  | 20.9±2.5  |
| Smoking                |        |        |           |
| None                   | 44 (28.9) | 56 (36.8) | 52 (34.3) |
| <20 cigarettes         | 12 (44.4) | 9 (33.3)  | 6 (22.3)  |
| \geq 20 cigarettes      | 5 (33.3)  | 7 (50.0)  | 4 (16.7)  |
| Alcohol drinking       |        |        |           |
| None                   | 43 (34.4) | 42 (33.6) | 41 (32.0) |
| Occasionally           | 10 (21.3) | 23 (48.9) | 14 (29.8) |
| Every day              | 8 (36.4)  | 7 (31.8)  | 7 (31.8)  |

Data are presented as number (%) or mean±SD.
OPZ, omeprazole; SD, standard deviation; BMI, body mass index.

5. Statistical evaluation

The proportion of successfully treated patients was compared for all treatment groups. Comparison between sufficient symptom relief and complete symptom relief of each drug group was performed by using chi-square test and correction of multiplicity was made using the Bonferroni correction. In addition, the proportion of improvement of each symptom after treatment was compared for all treatment groups using the same method. Before we started the study, it was decided that the p-value for the main comparison using the GOS score be corrected for multiplicity using the Bonferroni correction. All p-values for the primary and secondary outcome measures (GOS response at 4 weeks) were considered significant at p<0.05.

RESULTS

The flow chart in Fig. 1 describes the patients of the study. Of the 217 patients (82 male, 135 female; age range, 20 to 64 years; mean age, 44.5 years) who were enrolled at baseline observation, 196 were randomized to one of the three treatment groups. Of the 21 patients who were excluded, 15 were \[ H. pylori\] positive (presence of urinary anti-\[ H. pylori\] antibody), five had low scores on the symptom scale (GOS score, \leq 3), and one had an insufficient report of symptoms. One patient in the OPZ20 group was lost during the follow-up; therefore, 61 patients in the OPZ20 group, 72 in the OPZ10 group, and 62 in the on-demand group completed the study. Blinding of the site personnel to the study results for these patients was maintained until the end of the study. All patients’ compliance was good on the basis of the returned pill count.

The demographic baseline characteristics of the patients from each group are shown in Table 1. We compared the difference in gender, age, body mass index, smoking habit, and alcohol...
habit among the three treatment groups. At baseline, there were no statistically significant differences among the treatment groups. The demographic baseline characteristics were well balanced.

Table 2. Rate of Improvement after 4 Weeks of Treatment in Each Group

| Symptom               | Treatment group | Rate of improvement, % | No. | No. of patients with improvement | p-value (vs OPZ20) |
|-----------------------|-----------------|------------------------|-----|----------------------------------|--------------------|
| Stomach pain          | OPZ20           | 82                     | 54  | 44                               | 0.07               |
|                       | OPZ10           | 67                     | 63  | 42                               | 0.382              |
|                       | On-demand       | 75                     | 55  | 41                               |                    |
| Heartburn             | OPZ20           | 83                     | 54  | 45                               | 0.057              |
|                       | OPZ10           | 68                     | 66  | 45                               |                    |
|                       | On-demand       | 73                     | 60  | 44                               | 0.198              |
| Regurgitation         | OPZ20           | 85                     | 53  | 45                               | 0.037              |
|                       | OPZ10           | 68                     | 63  | 43                               |                    |
|                       | On-demand       | 75                     | 56  | 42                               | 0.198              |
| Postprandial fullness| OPZ20           | 84                     | 55  | 46                               | 0.016              |
|                       | OPZ10           | 68                     | 68  | 46                               |                    |
|                       | On-demand       | 75                     | 60  | 45                               | 0.255              |
| Vomiting              | OPZ20           | 76                     | 59  | 45                               | 0.110              |
|                       | OPZ10           | 56                     | 68  | 38                               |                    |
|                       | On-demand       | 63                     | 59  | 37                               | 0.307              |
| Belching              | OPZ20           | 79                     | 56  | 44                               | 0.153              |
|                       | OPZ10           | 66                     | 67  | 44                               |                    |
|                       | On-demand       | 76                     | 57  | 40                               | 0.328              |
| Early satiety        | OPZ20           | 83                     | 54  | 45                               | 0.001              |
|                       | OPZ10           | 72                     | 65  | 47                               |                    |
|                       | On-demand       | 76                     | 58  | 44                               | 0.072              |
| Bloating              | OPZ20           | 89                     | 54  | 48                               |                    |
|                       | OPZ10           | 61                     | 67  | 41                               | 0.072              |
|                       | On-demand       | 76                     | 58  | 44                               |                    |

OPZ, omeprazole.

Fig. 2. Frequency of symptoms in each treatment group at baseline. The main bothersome symptoms were postprandial fullness, bloating, and stomach pain.

Fig. 3. Percentage of patients exhibiting sufficient symptom relief after 4 weeks of treatment. The omeprazole (OPZ20) group exhibited significantly better results than the OPZ10 group (p<0.05) with respect to the primary outcome measure of symptom relief (Global Overall Symptom ≤2).
Our results demonstrated that treatment with omeprazole showed efficacy for upper abdominal symptoms relief in *H. pylori*-negative primary care patients with uninvestigated dyspepsia. In particular, omeprazole 20 mg was more effective for treatment of acid regurgitation, postprandial fullness, vomiting, and bloating than omeprazole 10 mg. However, there was no significant difference between omeprazole 20 mg and on-demand therapy.

van Zanten et al. \(^{17}\) (CADET-HN study) showed that treatment with omeprazole provides superior symptomatic relief compared to placebo in the treatment of *H. pylori*-negative primary care patients with uninvestigated dyspepsia. We compared the efficacy of different doses of omeprazole (20 and 10 mg) and different administration methods (daily and on-demand with omeprazole 20 mg) in *H. pylori*-negative dyspeptic patients at 4 weeks of treatment in our study, which is different from the CADET-HN study. We selected *H. pylori*-negative dyspeptic patients whose number may increase in the future in Japan. Recently, several studies showed that the rate of *H. pylori* infection gradually decreases in Japan. \(^{21-23}\) Our recent study \(^{24}\) showed that over a period of 25 years, between 1981 and 2005, the percentage of patients complaining of heartburn increased almost fivefold, and with respect to endoscopic findings, the prevalence of peptic ulcers decreased, whereas the number of patients with no abnormalities and erosive esophagitis increased. However, the rate of *H. pylori* infection and prevalence of gastric cancer are still high in the old generation in Japan; \(^{21-23}\) therefore, we selected dyspeptic patients whose age range was from 20 to 65 years. Considering these epidemiological results, it is possible to consider that, in the future in Japan, there will be fewer patients with peptic ulcers and more GERD patients or dyspeptic patients who display no endoscopic abnormalities. \(^{22-24}\)

The optimum therapeutic strategy for dyspepsia has not been well established in Japan. Recently, several pathophysiological mechanisms have been suggested, i.e., delayed gastric emptying, impaired gastric accommodation to a meal, hypersensitivity to gastric distension, *H. pylori* infection, altered duodenal sensitivity to lipids or acid, abnormal duodeno-jejunal motility or central nervous system dysfunction may play a role in dyspeptic symptoms. \(^{26}\) Therefore, it has been suggested that acid-suppressive drugs, novel prokinetics, eradication of *H. pylori*, antidepressants, fundus-relaxing drugs, antagonists of 5-hydroxytryptamine, cholecystokinin receptor antagonists, or traditional Japanese medicine (Kampo) would be efficacious treatment options for dyspeptic patients. \(^{27-28}\)

One of these mechanisms, the abnormality of gastric acid secretion, plays an important role in the occurrence of dyspepsia. In patients with FD, especially those with EPS, suppression of gastric acid secretion by antisecretory agents such as PPIs or H2RAs seems to ameliorate epigastric pain or burning, so-called GERD. Furthermore, even in PDS, as the initial gastric acid emptying may play a pathogenetic role on symptom generation through the early onset of duodenal brake, acid suppression might be effective, at least in part, against the bothersome symptom of postprandial fullness. \(^{29}\) PPIs are among the strongest drugs available for gastric acid suppression. Therefore, as shown in our study, daily treatment with omeprazole 20 mg was more effective, in particular, for acid regurgitation, postprandial fullness, vomiting, and bloating, than that with omeprazole 10 mg.

### Table 3. Percentage of Patients Showing Symptom Aggravation after 4 Weeks of Treatment

| Total no. of patients | No. of patients with aggravation | Rate, % |
|-----------------------|---------------------------------|---------|
| OPZ20                 | 61                              | 0       | 0.0     |
| OPZ10                 | 72                              | 0       | 0.0     |
| On-demand             | 62                              | 1       | 1.6     |

OPZ, omeprazole.
Unfortunately, our study has several limitations. First, in our methodology, our study was not a double-blind placebo controlled study. We did not select a placebo group or control group in our study. In the future, we will need to evaluate the efficacy of omeprazole for dyspeptic symptoms in a double-blind placebo controlled study. Usually, treatment with placebo showed an efficacy of about 20% to 30% in dyspeptic patients. The CADET-HN study showed that among responders, 51.1% responded to omeprazole treatment and 23.3% responded to placebo treatment. Therefore, in order to evaluate the exact efficacy of omeprazole in patients we will need to include a placebo group in future studies. Secondly, our selected dyspeptic patients did not exactly meet the criteria of the Rome III classification. The subjects of our study were defined as patients with chronic or recurrent upper abdominal symptoms within the past 3 months, although the Rome III classification is based on events that occurred in the past 6 months. However, this aspect needs to be further evaluated for Japanese dyspeptic patients. Recently, Manabe and Haruma proposed that the 6-month period after onset of dyspeptic symptoms, currently required for diagnosis of FD in the Rome III classification, should be shortened in the Japanese population, because for Japanese patients, the period between symptom onset and evaluation in the hospital is usually less than 6 months. Finally, among our selected dyspeptic patients were GERD patients. These patients had upper GI symptoms that included not only stomach pain, postprandial fullness, vomiting, early satiety, or bloating but also heartburn or regurgitation. FD is defined as symptoms that are thought to originate from the gastroduodenal region (in particular, epigastric pain or burning, postprandial fullness or early satiety) with differentiation between PDS and EPS. In our study, we included GERD patients because FD and GERD are among the most widely prevalent upper GI disorders in Japan, as well as in Western countries. In other words, both heartburn and regurgitation are typical symptoms of patients with GERD, and some GERD patients may present with typical FD symptoms such as epigastric pain and epigastric burning without any endoscopic mucosal lesions. On the other hand, some FD patients may have reflux symptoms. Therefore, there is an overlap between dyspeptic and reflux symptoms.

A systematic review demonstrated that on-demand therapy with currently available PPIs appears to be effective in the long-term management of patients with nonerosive reflux disease or mild and uninvestigated forms of GERD. Randomized-controlled clinical trials in either form of GERD have shown that PPIs are superior to placebo and H,RA for controlling symptoms. However, the efficacy of on-demand therapy with omeprazole for FD is not well known. In the data about GOS and each symptoms, there was no difference of efficacy between continuous omeprazole 20 mg therapy and on-demand therapy. In addition, only one patient in the on-demand group had symptom aggravation during the study period. However, major side effects were not observed in the three treatment groups.

In summary, our results demonstrated that treatment with omeprazole was efficient for upper abdominal symptoms relief in H. pylori-negative primary care patients with uninvestigated dyspepsia. Dyspeptic patients who experience acid regurgitation, postprandial fullness, vomiting, and bloating may be more applicable to continuous omeprazole 20 mg than omeprazole 10 mg. In the future, we will need to evaluate the long-term efficacy of omeprazole for dyspeptic symptoms.

**CONFLICTS OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**REFERENCES**

1. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999;45 Suppl 2:i37-i42.
2. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130:1466-1479.
3. Kawamura A, Adachi K, Takashima T, et al. Prevalence of functional dyspepsia and its relationship with Helicobacter pylori infection in a Japanese population. J Gastroenterol Hepatol 2001;16:384-388.
4. Stanghellini V. Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999;231:20-28.
5. Jones RH, Lydeard SE, Hobbs FD, et al. Dyspepsia in England and Scotland. Gut 1990;31:401-405.
6. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ 3rd. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992;102(4 Pt 1):1259-1268.
7. Fass R. Proton pump inhibitor failure: what are the therapeutic options? Am J Gastroenterol 2009;104 Suppl 2:S33-S38.
8. Pueca DA, Gudmundson J, Siepman N, Pilmer BL, Freston J. Proton pump inhibitors: effective first-line treatment for management of dyspepsia. Dig Dis Sci 2007;52:983-987.
9. North of England Dyspepsia Guideline Development Group. Dyspepsia: managing dyspepsia in adults in primary care. Newcastle upon Tyne: University Newcastle upon Tyne, 2004.
10. Talley NJ, Meineche-Schmidt V, Paré P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998;12:1055-1065.
11. Blum AL, Arnold R, Stolte M, Fischer M, Koelz HR. Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group. Gut 2000;47:473-480.
placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut 2002;51:502-506.
13. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006;(4):CD001960.
14. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001;96:689-696.
15. Moayyedi P, Delaney BC, Vakil N, Forman D, Talley NJ. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004;127:1329-1337.
16. Wang WH, Huang JQ, Zheng GF, et al. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol 2007;5:178-185.
17. Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, et al. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. Am J Gastroenterol 2005;100:1477-1488.
18. Junghard O, Lauritsen K, Talley NJ, Wiklund IK. Validation of seven graded diary cards for severity of dyspeptic symptoms in patients with non ulcer dyspepsia. Eur J Surg Suppl 1998;583(1):106-111.
19. Graham DY, Reddy S. Rapid detection of anti-Helicobacter pylori IgG in urine using immunochromatography. Aliment Pharmacol Ther 2001;15:699-702.
20. Sjöstedt S, Befrits R, Sylvan A, et al. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2005;22:183-191.
21. Akamatsu T, Ichikawa S, Okudaia S, et al. Introduction of an examination and treatment for Helicobacter pylori infection in high school health screening. J Gastroenterol 2011;46:1353-1360.
22. Nakajima S, Nishiyama Y, Yamaoka M, Yasaoka T, Cho E. Changes in the prevalence of Helicobacter pylori infection and gastrointestinal diseases in the past 17 years. J Gastroenterol Hepatol 2010;25 Suppl 1:S99-S110.
23. Kawai T, Yamamoto K, Fukuzawa M, et al. Helicobacter pylori infection and reflux esophagitis in young and middle-aged Japanese subjects. J Gastroenterol Hepatol 2010;25 Suppl 1:S80-S85.
24. Manabe N, Haruma K, Kamada T, et al. Changes of upper gastrointestinal symptoms and endoscopic findings in Japan over 25 years. Intern Med 2011;50:1357-1363.
25. Yamaoka M, Nakajima S. Prevalence of subjects at a high or very high risk of gastric cancer in Japan. Gut Liver 2009;3:95-100.
26. Tack J, Lee KJ. Pathophysiology and treatment of functional dyspepsia. J Clin Gastroenterol 2005;39(5 Suppl 3):S211-S216.
27. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004;127:1239-1255.
28. Kusunoki H, Haruma K, Hata J, et al. Efficacy of Rikkunshito, a traditional Japanese medicine (Kampo), in treating functional dyspepsia. Intern Med 2010;49:2195-2202.
29. Grudell AB, Camilleri M, Burton DD, Stephens DA. Effect of a proton pump inhibitor on postprandial gastric volume, emptying and symptoms in healthy human subjects: a pilot study. Aliment Pharmacol Ther 2006;24:1037-1043.
30. Manabe N, Haruma K. Diagnosis and treatment of dyspeptic patients in Japan. J Gastroenterol Hepatol 2011;26 Suppl 3:27-31.
31. Pace F, Tonini M, Pallotta S, Molteni P, Porro GB. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken ‘on-demand’. Aliment Pharmacol Ther 2007;26:195-204.
32. Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet 2006;367:2086-2100.
33. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005;(2):CD003245.